Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis (NASH NAFLD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Saif Abu Mouch, MD
- Phone Number: 972-506-246-966
- Email: saif@hy.health.gov.il
Study Locations
-
-
-
Hadera, Israel, 38100
- Hillel Yaffe Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients suffering from Steatohepatitis
- Patients suffering from Liver Steatosis
Exclusion Criteria:
- Patients suffering from viral hepatitis
- Patients with HIV infection
- Patients suffering from Wilsons Disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Nigella Sativa Supplement
Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
|
|
|
Active Comparator: Patients receiving a placebo tablet
Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
|
Capsules that contain a placebo but look like the Nigella Sativa capsules
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of Nigella Sativa on Liver Triglyceride Concentration
Time Frame: One year
|
The difference in change in the average liver triglyceride concentration will be measured by MRI Spectroscopy between the Nigella Sativa arm and the placebo arm, at start and end of the study.
|
One year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of Nigella Sativa on Improvement in NASH Activity Index
Time Frame: One year
|
Improvement in Nash activity Index will be measured by the NAFLD Activity Score.
|
One year
|
|
Effect of Nigella Sativa on Fibrosis Staging
Time Frame: One year
|
Microscopic examination of two liver biopsies at start and end of the study, to determine fibrosis staging.
|
One year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0002-14-HYMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis
-
NCT03861819CompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver
-
NCT02781584CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)
-
NCT01265498CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)
-
NCT04833140RecruitingNASH - Nonalcoholic Steatohepatitis
-
NCT04972396CompletedNASH - Nonalcoholic Steatohepatitis
-
NCT04767529CompletedNASH - Nonalcoholic Steatohepatitis
-
NCT05692492Active, not recruitingNonalcoholic Steatohepatitis (NASH)
-
NCT03332940TerminatedNonalcoholic Steatohepatitis | NASH - Nonalcoholic Steatohepatitis
-
NCT04134091CompletedNonalcoholic Steatohepatitis (NASH)
-
NCT04521114CompletedNonalcoholic Steatohepatitis (NASH)
Clinical Trials on Nigella Sativa
-
NCT03208790Completed
-
NCT07447349Completed
-
NCT07494279Not yet recruiting
-
NCT07315555Not yet recruitingCommunity Acquired Pneumonia
-
NCT01393054Unknown
-
NCT04553705Completed
-
NCT00327054CompletedHypertension | Diabetes Mellitus | Hypercholesterolemia | Metabolic Syndrome X
-
NCT07055763Active, not recruiting